E.A.M. Gale

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

C. J. Currie, C Poole, E.A.M. Gale · Diabetologia · 2009 · 1.1K citations · Full text

Glucose-lowering Therapies, Diabetes Management, Oncology +7

SELF-MONITORING OF BLOOD-GLUCOSE

S Walford, E.A.M. Gale, S.P. Allison et al. · The Lancet · 1978 · 267 citations

Measurement, Diabetes, Wearable Technology +2

Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity

Ezio Bonifacio, Stefano Genovese, S. Braghi et al. · Diabetologia · 1995 · 178 citations · Full text

Islet Autoantibody Markers, Autoimmune Disease, High Sensitivity +9

The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice

Alberto Signore, Paolo Pozzilli, E.A.M. Gale et al. · Diabetologia · 1989 · 146 citations · Full text

Autoimmune Disease, Immune Regulation, Natural History +9

Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials.

P. J. Bingley, Alistair J.K. Williams, E.A.M. Gale · Diabetes Care · 1999 · 94 citations